NASDAQ : AAPG
Ascentage Pharma Group International — Key statistics
Healthcare · Biotechnology · China
Last price 14.4565 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.27B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.27B |
| Enterprise Value | 1.31B |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 19, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 373.25M |
| Shares Change (YoY) | +13.76% |
| Shares Change (QoQ) | +0.70% |
| Owned by Insiders (%) | 12.90% |
| Owned by Institutions (%) | 19.22% |
| Float | 281.90M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.48 |
| Forward PS | 11.47 |
| PB Ratio | 15.31 |
| P/TBV Ratio | 17.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 13.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.22 |
| Quick Ratio | 1.09 |
| Debt / Equity | 3.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.57 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -236.63% |
| Return on Assets (ROA) | -28.04% |
| Return on Invested Capital (ROIC) | -34.90% |
| Return on Capital Employed (ROCE) | -103.92% |
| Weighted Average Cost of Capital (WACC) | 6.74% |
| Revenue Per Employee | $114,258 |
| Profits Per Employee | -$261,127 |
| Employee Count | 828 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 1.07 |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.22M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -56.72% |
| 50-Day Moving Average | 15.87 |
| 200-Day Moving Average | 20.33 |
| Relative Strength Index (RSI) | 42.14 |
| Average Volume (20 Days) | 8,196 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 18,161 |
| Short Previous Month | 9,250 |
| Short % of Shares Out | 0.02% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.74 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 94.61M |
| Gross Profit | 88.86M |
| Operating Income | -207.64M |
| Pretax Income | -214.07M |
| Net Income | -216.21M |
| EBITDA | -196.66M |
| EBIT | -207.64M |
| Loss Per Share | -$2.32 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 279.06M |
| Total Debt | 308.35M |
| Net Cash | -29.29M |
| Net Cash Per Share | -$0.08 |
| Equity (Book Value) | 83.30M |
| Book Value Per Share | 0.22 |
| Working Capital | 60.32M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -198.76M |
| Capital Expenditures | -2.91M |
| Depreciation & Amortization | 11.20M |
| Net Borrowing | 55.35M |
| Free Cash Flow | -201.68M |
| FCF Per Share | -$0.54 |
Margins
| Measure | Value |
|---|
| Gross Margin | 93.93% |
| Operating Margin | -219.48% |
| Pretax Margin | -226.27% |
| Profit Margin | -228.54% |
| EBITDA Margin | -207.87% |
| EBIT Margin | -219.48% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -13.76% |
| Shareholder Yield | -13.76% |
| Earnings Yield | -16.08% |
| FCF Yield | -15.82% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $44.50 |
| Price Target Difference | 207.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 45.37% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.14 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |